BNIPL‑2 expression is correlated with the prognosis and regulates the proliferation of colorectal cancer through CD44

Lei Gao, Hansong Liu, Ningwei Yin, Shanshan Zuo, Guangli Jin, Yangxi Hu, Desheng Hu, Ying Li, Qiong Song*, Xuejie Fei

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Colorectal cancer (CRC) currently leads to many deaths worldwide. The regulatory mechanism, however, remains largely unclear. In the present study, bioinformatics methods were used to identify genes associated with CRC prognosis and to detect the molecular signals regulating the cell cycle in two CRC cell lines. It was revealed that BNIPL-2 expression was higher in CRC tissues than in adjacent tissue samples. Upregulation of BNIPL-2 was correlated with poor prognosis and the adverse malignant stages T and M. BNIPL-2 was also associated with signaling pathways involved in cancer cell growth. BNIPL-2 overexpression promoted cell proliferation and increased the proportion of cells in the G2/M phase. Knockdown of BNIPL-2 inhibited cell proliferation. CD44 was regulated by BNIPL-2 and promoted cell proliferation. Downregulation of CD44 suppressed cell proliferation and rescued the cell proliferation promoted by BNIPL-2. Overexpression of CD44 restored the cell proliferation suppressed by BNIPL-2 knockdown. The present study not only suggested that BNIPL-2 may be a potential biomarker of CRC but also indicated that BNIPL-2 regulates CRC cancer proliferation via CD44, which could be a diagnostic and clinical treatment target.

Original languageEnglish
Pages (from-to)4073-4080
Number of pages8
JournalMolecular Medicine Reports
Volume20
Issue number5
DOIs
Publication statusPublished - 2019
Externally publishedYes

Keywords

  • BNIPL-2
  • CD44
  • Cell cycle
  • Colorectal cancer
  • Prognosis
  • Proliferation
  • Stage

Fingerprint

Dive into the research topics of 'BNIPL‑2 expression is correlated with the prognosis and regulates the proliferation of colorectal cancer through CD44'. Together they form a unique fingerprint.

Cite this